Download PDF
Aktuelle Rheumatologie 2013; 38(05): 280-287
DOI: 10.1055/s-0033-1358391
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Riesenzellarteriitis und Takayasu Arteriitis: Klinische Aspekte, Diagnostik und Therapie

Giant Cell Arteritis and Takayasu Arteritis: Clinical Aspects, Diagnostics and Therapy
A. D. Wagner
1   Hannover Medical School, Department of Nephrology, Hannover
,
W. A. Schmidt
2   Immanuel Krankenhaus Berlin, Rheumaklinik Berlin-Buch, Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
25 October 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Riesenzellarteriitis (RZA) ist die häufigste systemische Vaskulitis im Erwachsenenalter, und betrifft die großen und mittelgroßen Arterien. Die Takayasu Arteriitis (TA) ist auch eine Vaskulitis der großen Gefäße und tritt Im Gegensatz zur RZA typischerweise vor dem 40. Lebensjahr auf. Sie ist die dritthäufigste Vaskulitis im Kindesalter. Beide Großgefäßvaskulitiden können zu gefürchteten ischämischen Komplikationen im Bereich der Extremitäten oder der viszeralen Organe führen. Aus diesem Grunde ist eine frühzeitige Diagnosestellung von großer Bedeutung. Die häufigste Komplikation der RZA ist die anteriore ischämische Optikusneuropathie, welche unbehandelt zur Erblindung führen kann. In jedem Fall soll die Diagnose histologisch oder sonografisch bestätigt werden. Die Temporalarterienbiopsie oder Bildgebung sollte so früh wie möglich stattfinden, den Therapiebeginn bei dringendem klinischem Verdacht jedoch nicht verzögern. Desweiteren haben bei der TA die Angiografie und bei beiden Großgefäß­vaskulitiden im Hinblick auf die Erstdiagnostik und die Verlaufsbeobachtung die Magnetresonanzangiografie, die CT-Angiografie, die Positronenemis­sionstomografie und nicht zuletzt der Ultraschall einen hohen Stellenwert. Sowohl die RZA als auch die TA zeichnen sich durch ein Ansprechen auf Kortikosteroide aus. Die Rolle von Immunsuppressiva ist noch nicht vollständig geklärt. Bei der Behandlung der RZA liegen derzeit zu Methotrexat als Kortikosteroid sparende Therapie die meisten Daten vor. Im Rahmen der Takayasu Arteriitis haben die TNFalpha-Blocker eine Bedeutung.

Abstract

Giant cell arteritis (GCA) is the most common systemic vasculitis and affects large and medium-sized vessels. Takayasu arteritis (TA) is the second vasculitis of the large-sized vessels and affects young adults under 40 years of age. TA is the third most common vasculitis in children. Both vasculitides can cause ischaemic complications of extremities and visceral organs. The most common complication of GCA is ischaemia of the optic nerve causing irreversible blindness. Besides, dissection of aortic aneurysms, cerebral ischaemia, ischaemia of limbs or organs as well as tongue necrosis may occur. Diagnosis shoud be confirmed by biopsy or sonography but diagnostic procedures shoud not delay therapy. In addition, angiography is important as a diagnostic procedure in TA. In both large-sized vasculitides magnetic resonance angiography, computed tomography angiography, positron emission tomography and last but not least colour Dopler ultrasonography enable early diagnosis and the monitoring of responses to treatment. Cortico­steroids are the therapy of choice in the treatment of GCA and TA. Disease-modifying drugs particularly methotrexate have a corticosteroid sparing effect in GCA. In contrast, TNF-blocking agents are effective in the treatment of TA.

Schlüsselwörter

Arteriitis temporalis - Takayasu Arteriitis - Polymyalgia rheumatica - Sonografie - Glukokortikoide

Key words

temporal arteritis - Takayasu arteritis - polymyalgia rheumatica - ultrasound - glucocorticoids
 

  • Literatur

  • 1 Smetana GW, Shmerling RH. Does this patient have temporal arteritis?. JAMA 2002; 287: 92-101
    CrossrefPubMedGoogle Scholar
  • 2 Schirmer M, Dejaco C, Schmidt WA. Riesenzellarteriitis: Update – Diag­nose und Therapie. Z Rheumatol 2012; 71: 754-759
    CrossrefPubMedGoogle Scholar
  • 3 Schmidt WA. Polymyalgia rheumatica. Z Rheumatol 2013; 72: 59-65
    CrossrefPubMedGoogle Scholar
  • 4 Schmidt WA. Current diagnosis and treatment of temporal arteritis. Curr Treat Options Cardiovasc Med 2006; 8: 145-151
    CrossrefPubMedGoogle Scholar
  • 5 Schmidt WA. Imaging in vasculitis. Best Pract Res Clin Rheumatol 2013; 27: 107-118
    CrossrefPubMedGoogle Scholar
  • 6 Ness T, Bley T, Schmidt WA et al. The diagnosis and treatment of giant cell arteritis. Dtsch Arztebl Int 2013; 110: 376-386
    PubMedGoogle Scholar
  • 7 Schmidt WA, Seifert A, Gromnica-Ihle E et al. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford) 2008; 47: 96-101
    CrossrefPubMedGoogle Scholar
  • 8 Schmidt WA, Moll A, Seifert A et al. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford) 2008; 47: 1406-1408
    CrossrefPubMedGoogle Scholar
  • 9 Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-1128
    CrossrefPubMedGoogle Scholar
  • 10 Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-323
    CrossrefPubMedGoogle Scholar
  • 11 Schirmer M, Dejaco C, Schmidt WA. Riesenzellarteriitis: Update – Diag­nose und Therapie. Z Rheumatol 2012; 71: 754-759
    CrossrefPubMedGoogle Scholar
  • 12 Hauenstein C, Reinhard M, Geiger J et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Rheumatology (Oxford) 2012; 51: 1999-2003
    CrossrefPubMedGoogle Scholar
  • 13 Schmidt WA, Kraft HE, Vorpahl K et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336-1342
    CrossrefPubMedGoogle Scholar
  • 14 Schmidt WA, Wagner AD. Role of imaging in diagnosis of and differentiation between vasculitides. Future Rheumatol 2006; 1: 627-634
    CrossrefPubMedGoogle Scholar
  • 15 Schmidt WA. Extraartikuläre Sonografie bei rheumatischen Erkrankungen. Akt Rheumatol 2010; 35: 312-317
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Aschwanden M, Daikeler T, Kesten F et al. Temporal artery compression sign – a novel ultrasound finding for the diagnosis of giant cell arteritis. Ultraschall Med 2013; 34: 47-50
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Bley TA, Weiben O, Uhl M et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum 2005; 52: 2470-2477
    CrossrefPubMedGoogle Scholar
  • 18 Bley TA, Ostendorf B, Scherer A et al. Magnetresonanzangiographie in der Rheumatologie. Z Rheumatol 2012; 71: 430-435
    CrossrefPubMedGoogle Scholar
  • 19 Hauenstein C, Reinhard M, Geiger J et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Rheumatology (Oxford) 2012; 51: 1999-2003
    CrossrefPubMedGoogle Scholar
  • 20 Schmidt WA, Gromnica-Ihle E. Polymyalgia rheumatica und Riesenzellarteriitis (Arteriitis temporalis). In: Busse O, Fleig WE, Mayet WJ. et al. Hrsg Rationelle Diagnostik und Therapie in der Inneren Medizin: Leitlinien-basierte Empfehlungen für die Praxis. München: Elsevier Deutschland; 2011
    Google Scholar
  • 21 Berlit P, Gross WL, Herrlinger U et al. Zerebrale Vaskulitis. Leitlinien der Deutschen Gesellschaft für Neurologie 2008; http://www.dgn.org/images/stories/dgn/leitlinien/LL2008/ll08kap_033.pdf
    PubMedGoogle Scholar
  • 22 Blockmans D, Bley T, Schmidt W. Imaging for large-vessel vasculitis. Curr Opin Rheumatol 2009; 21: 19-28
    CrossrefPubMedGoogle Scholar
  • 23 Prieto-González S, Arguis P, García-Martínez A et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 2012; 71: 1170-1176
    CrossrefPubMedGoogle Scholar
  • 24 Karassa FB, Matsagas MI, Schmidt WA et al. Diagnostic performance of ultrasonography for giant-cell arteritis: a meta-analysis. Ann Intern Med 2005; 142: 359-369
    CrossrefPubMedGoogle Scholar
  • 25 Czihal M, Zanker S, Rademacher A et al. Sonographic and clinical pattern of extracranial and cranial giant cell arteritis. Scand J Rheumatol 2012; 41: 231-236
    CrossrefPubMedGoogle Scholar
  • 26 Bley TA, Reinhard M, Hauenstein C et al. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum 2008; 58: 2574-2578
    CrossrefPubMedGoogle Scholar
  • 27 Hayreh SS. Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management. Eye 1990; 4: 25-41
    CrossrefPubMedGoogle Scholar
  • 28 Dasgupta B, Cimmino MA, Maradit-Kremers H et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71: 484-492
    CrossrefPubMedGoogle Scholar
  • 29 Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-323
    CrossrefPubMedGoogle Scholar
  • 30 Nesher G, Berkun Y, Mates M et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332-1337
    CrossrefPubMedGoogle Scholar
  • 31 Lee MS, Smith SD, Galor A et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54: 3306-3309
    CrossrefPubMedGoogle Scholar
  • 32 Mahr AD, Jover JA, Spiera RF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-2797
    CrossrefPubMedGoogle Scholar
  • 33 Hoffman GS, Cid MC, Rendt-Zagar KE et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-630
    CrossrefPubMedGoogle Scholar
  • 34 Czihal M, Piller A, Schroettle A et al. Outcome of giant cell arteritis of the arm arteries managed with medical treatment alone: cross-sectional follow-up study. Rheumatology (Oxford) 2013; 52: 282-286
    CrossrefPubMedGoogle Scholar
  • 35 Vaideeswar P, Deshpande JR. Pathology of Takayasu arteritis: A brief review. Ann Pediatr Cardiol 2013; 6: 52-58
    CrossrefPubMedGoogle Scholar
  • 36 Weiss PF. Pediatric vasculitis. Pediatr Clin N Am 2012; 59: 407-423
    CrossrefPubMedGoogle Scholar
  • 37 Richards BL, March L, Gabriel SE. Epidemiology of large-vessel vasculitides. Best Pract Res Clin Rheumatol 2010; 24: 871-873
    CrossrefPubMedGoogle Scholar
  • 38 Lupi-Herrera E, Sanchez-Torres G, Marcushamer J et al. Takayasu’s arteritis. Clinical study of 107 cases. American Heart Journal 1977; 93: 94-103
    CrossrefPubMedGoogle Scholar
  • 39 Strachnan RW. The nature history of Takayasu’s arteriopathy. Quaterly Journal of Medicine 1964; 33: 57
    PubMedGoogle Scholar
  • 40 Hall S, Barr W, Lie JT et al. Takayasu arteritis. A study of 32 North American patients. Medicine 1985; 64: 89-99
    PubMedGoogle Scholar
  • 41 Al Abrawi S, Fouillet-Desjonqueras M, David L et al. Takayasu arteritis in children. Pediatr Rheumatol Online J 2008; 6: 17
    CrossrefPubMedGoogle Scholar
  • 42 Ogawa O, Watanabe R, Shimizu H et al. Hypertensive crisis in young woman with Takayasu arteritis. Intern Med 2011; 50: 1963-1967
    CrossrefPubMedGoogle Scholar
  • 43 Kerr GS, Hallahan CW, Giordano J et al. Takayasu arteritis. Ann Intern Med 1994; 120: 919
    CrossrefPubMedGoogle Scholar
  • 44 Arend WP, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-1134
    PubMedGoogle Scholar
  • 45 Kissin EY, Merkel PA. Diagnostic imaging in Takayasu arteritis. Curr Opin Rheumatol 2004; 16: 31-37
    CrossrefPubMedGoogle Scholar
  • 46 Bezerra Lira-Filho E, Campos O, Lazaro Andrade J et al. Thoracic aorta evaluation in patients with Takayasu’s arteritis by transesophageal echocardiography. J Am Soc Echocardiogr 2006; 19: 829-834
    PubMedGoogle Scholar
  • 47 Soto ME, Espinola-Zavaleta N, Ramirez-Quito O et al. Echocardiographic follow-up of patients with Takayasu’s arteritis: five-year survival. Echocardiography 2006; 23: 353-360
    CrossrefPubMedGoogle Scholar
  • 48 Both M, Jahnke T, Reinhold-Keller E et al. Percutaneous management of occlusive arterial disease associated with vasculitis: a single center experience. Cardiovasc Intervent Radiol 2003; 26: 19-26
    CrossrefPubMedGoogle Scholar
  • 49 Webb M, Chambers A, AL-Nahhas A et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 2004; 31: 627-634
    CrossrefPubMedGoogle Scholar
  • 50 Yamada I, Nakagawa T, Himeno Y et al Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. J Magn Reson Imaging 2000; 11: 481-487
    CrossrefPubMedGoogle Scholar
  • 51 Tso E, Flamm SD, White RD et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002; 46: 1634-1642
    CrossrefPubMedGoogle Scholar
  • 52 Khandelwal N, Kalra N, Garg MK et al. Multidetector CT angiography in Takayasu arteritis. Eur J Radiol 2011; 77: 369-374
    CrossrefPubMedGoogle Scholar
  • 53 Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005; 17: 16-24 Review
    CrossrefPubMedGoogle Scholar
  • 54 Hoffman GS, Merkel PA, Brasington RD et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50: 2296-2304
    CrossrefPubMedGoogle Scholar
  • 55 Hoyer BF, Mumtaz IM, Loddenkemper K et al. Takayasu Arteritis is characterized by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012; 71: 75-79
    CrossrefPubMedGoogle Scholar
  • 56 Kitazawa K, Joh K, Akizawa T. A case of lupus nephritis coexisting with podocytic infolding associated with Takayasu’s arteritis. Clin Exp Nephrol 2008; 12: 462-466
    CrossrefPubMedGoogle Scholar
  • 57 Sano N, Kitazawa K, Totsuka D et al. A case of lupus nephritis with alteration of the glomerular basement membrane associated with Takayasu’s arteritis. Clin Nephrol 2002; 58: 161-165
    PubMedGoogle Scholar
  • 58 Saxe PA, Altman RD. Takayasu’s arteritis syndrome associated with sistemi lupus erythematosus. Semin Arthritis Rheum 1992; 21: 295-305
    CrossrefPubMedGoogle Scholar
  • 59 Wada Y, Nishida H, Kohno K et al. AA amyloidosis in Takayasu’s arteritis-long-term survival on maintenance haemodialysis. Nephrol Dial Transplant 1999; 14: 2478-2481
    CrossrefPubMedGoogle Scholar
  • 60 Koga T, Nishino Y, Makiyama J et al. Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu‘s arteritis. Rheumatol Int 2010; 30: 561-563
    CrossrefPubMedGoogle Scholar
  • 61 Cavatorta F, Campisi S, Trabassi E et al. IgA nephropathy associated with Takayasu‘s arteritis: report of a case and review of the literature. Am J Nephrol 1995; 15: 165-167
    CrossrefPubMedGoogle Scholar
  • 62 Jghaimi F, Kabbaj A, Essaadouni L. Takayasu’s arteritis and retroperitoneal fibrosis: a case report. Rev Med Interne 2010; 31: 1-3
    PubMedGoogle Scholar